What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist with proven efficacy for weight management and glycemic control. FDA-approved as Ozempic (diabetes) and Wegovy (weight management), it mimics the incretin hormone GLP-1 to regulate appetite and blood sugar.
Key Benefits & Mechanisms
Significant weight loss (15-20% body weight)
Improved glycemic control and insulin sensitivity
Reduced cardiovascular risk
Appetite suppression and reduced food cravings
Improved metabolic biomarkers
Potential neuroprotective effects
Reduced systemic inflammation
Research Summary
Semaglutide has the most robust clinical evidence of any peptide in this database. Multiple Phase III trials (STEP, SUSTAIN programs) demonstrate 15-20% body weight reduction. FDA-approved with extensive safety data.